

## JAGSONPAL PHARMACEUTICALS LIMITED

Regd Office (1-210). Shanpor Jat. New Delhi - 116 049 (INDIA) Fax 009111 26498941 26494 56 Phone 0091-11-26494619-24

### CIN NO:- L7489504 1978PLCD001R1 Unaudited Financial Results for the Quarter / Half year ended 31.12.2014

	Particulars						
	, and and an	3 months ended 31 12:2014	3 months ended 30.09,2014	3 months anded 31.12.2013	9 Months ended 31.12.2014	9 Months ended 31.12.2013	Rs, in lacs 12 Months Ended 31.03,2014
1		Unaudited	Unaudited	Un-audited	Unaudited	Un-audited	Audited
b	Other Operating Income	3242 <b>8</b> G	3298 OH	3770 16	0930.23	11257.01	14365.09
2	Total Income from operations (net) Expenses	3242.85	3296.06	3770.16	9930.23	11257 01	14306 191
ā						112.77 () (	14385.09
b	Purchases of stock-in-trade	1567.32	1903.77	1457 69	4422.71	4414.50	5461,64
Ċ		50.18 -48.08	347.08 959.78	305.49	606 89	729.42	1294.90
d.	contrava contente expenses	744.79	754.6	132 95 913.54	-443.02	653 24	-285 04
e.		71 75	71.81	73.90	2394.37 214.56	2761.41	3783.43
ſ	Other expenses	742,01	813.35	660.96	2226.03	214.03 2001.53	282.54
2	Total expenses	3127.98	3120.83	3544 54	9421,64	10774.13	3063 27 13599,84
•	Profit from Operations before Other Income. Finance Cost and Exceptional items (1-2)				, ., .	19774.13	13339.04
4	Otter Income	114.88	175.23	225.62	508.59	482 AS	785.26
5		0 41 115 29	2.03		5.55	0.00	6.07
	Exceptional rioms (3+4)	113 2::	177.26	225.6Z	514 14	482.6a	781.32
6 7	Futerice Cost	112.01	107.54	108 22	340 16	355.03	F30.40
′	Fronti from ordinary activities after finance cost but before	3.28	89.72	117 40	173.98	127.85	538 19 253 13
8	Exceptional Items (5-6) Exceptional Items				110.50	12, 103	200 13
9	Profit(+)/Loss(-) from Ordinary Activities before tax (7+8)	3 28	69 72	117 40	173,98	127.85	253.13
	(ax expense	0.66	33.55				
11	Net Profit/Loss(-) from Ordinary Activities after tax (9-10)	2.62	33.00 36.72	28.48	63.66	37 98	4106
32	t-ximordinally tlems (net of tax expense Rs., locs)	2.32	30.72	88 92	118 32	89.87	212 07
13	Net Profit +)/Loss(-) for the period(11.12)	2.62	36.72	88 92	110.32	55.67	
14 15	Minonty interest			00 32	110.32	89.87	212.07
16	Net Profit/(Loss) after taxes, minority interest and share of	2.52	36.72	88 92	119 32	89.87	
1/		1309.90	1309.90	1309 90	1309 30	1309.90	212 07 1309.90
10	Reserves excluding Revaluation reserves as par Balance shost of pr. Accounting yi				1040.00	1309 90	1.100.80
19.	Earnings Per Share (before extraordinary items)						7298.31
a.	Basic (R5.)	0.01					
ь	Diluted (Hs.)	0.01	0.14	0.34	Q 42	0.34	0.81
19.0	Earnings Por Share (after extraordinary items)	0.01	0,14	0.34	0.42	0 34	0.61
-	DOUG (H5.)	0.01	0.14	0.34	0.42		
b	Orluted (Rs.)	0.01	0.14	0.34	0.42	0.34 0.34	ប៉ូ <i>មូ</i> រ 081
A 1	PARTICULARS OF SHAREHOLDING Public Shereholding				V.12	0.50	0 61
1	- Number of shares						
	- Percentage of Strateholding	8076680	8076480	8962300	6076680	8962360	8902360
2	Promoter and promoter group sharsholding	30 83%	30.83%	34.21%	30.83%	34.21%	34.21%
<b>A</b>	Ptedged / nncumbered Number of shares						
-	Percentage of sharos (as a % of the total shareholding of Promoter and premoter group)						
٠	Percentage of shares (as a % of the lotal share capital of the Continuity)						
В	Non - cacumbered						
	Number of sitares	18121320	19121320	.74	-4		
-	Percentage of shares (es a % of the total shareholding of	100%	150%	17233640 100%	161Z13Z0	17235640	17235640
	Promoter and promoter group)		10074	100%	100%	100%	100%
	Percentage of shares (as a % of the total share capital of the	69.17%	69 17%	65,79%	69.17%	65,79%	65 79%
	Company) INVESTOR COMPLAINTS					70.7273	-/-/ / 570
	Pending at the beginning of the quarter						
	Received during the quarter	5 23					
	Disposed of during the quarter	23					
	Remaining unresolved at the end of the quarter	0					
Notes	a Daniella d'Errana a Daniella d'Errana	•					

- 1. The Unaudited Financial Results for the Quarter unded 31.12.2014, have been reviewed by the Audit Committee. The Board The consumed meaning results for the Guarter anneal 31.12.2014 have been reviewed by the Audit Committee. The Directors has approved the financial Rosults at its meeting held on 13.02.2015.
   The Company is operating only in the Phermacouticals segment and hence compliance has been made under AS-17.
   The not effect of the deterred taxation for the Quarter as per AS-22 has been taken.

4 Provious year figures have been regrouped / reatranged wherever intoessary



By Order of the Board For Jagsonphi/Pharmaceutica

Rajpal Singh Kechhar Managing Director DIN No 00059492

Place New Delhi Date : 13,02,2015

# P.P. THUKRAL & CO. CHARTERED ACCOUNTANTS

42, Ground Floor, World Trade Centre, Babar Road, New Delhi - 110 001 Ph. (O): 23413486

E-mail : sureshsethi62@yahoo.com

# LIMITED REVIEW REPORT FOR JAGSONPAL PHARMACEUTICALS LIMITED

## TO WHOM IT MAY CONCERN

We have reviewed the accompanying statement of unaudited financial results of Jagsonpal Pharmaceuticals Limited for the period ended 31.12.2014, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for P. P. THUKRAL & CO., Chartered Accountants

Place : New Delhi Date : 13.02.2015 PARTNER F.R. No. 000632 N

Membership no. 89318

SURESH SETHI